The downgrade to Equal-Weight suggests that Morgan Stanley believes Endava's stock performance will align with the market or sector average, indicating a neutral outlook. However, the increase in price target to $80 implies a positive view on the company's valuation, which could counterbalance the downgrade's impact. The mixed signals may result in a neutral short-term impact on the stock price.